BioSpace News Archive

Theralink Technologies is excited to announce groundbreaking work by George Mason University and the University of California, San Francisco, recently published in Cell Reports Medicine.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”) today announced a positive outcome from its recent Type C meeting with the U.S. Food and Drug Administration (FDA), held on Thursday, December 14, 2023 to discuss a full data review of the Company’s Trappsol® Cyclo™ clinical development program

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, announced that the U.S. Food and Drug Administration has cleared Align’s Invisalign® Palatal Expander System* for commercial availability in the U.S.

IAVI today announced that the Bill & Melinda Gates Foundation has awarded IAVI US$55 million to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults.

Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined the Nexcella Scientific Advisory Board.

Agilent Technologies Inc. (NYSE: A) today announced that CEO Mike McMullen and CFO Bob McMahon will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 9, 2024, at 9:45 a.m. Pacific Time.

Agno Pharma, a US-based, global pharmaceutical contract development and manufacturing organization, announced that it will acquire the Lubrizol Particle Sciences Inc. business.

FamGenix and Spesana, two leading health-tech companies, are thrilled to announce a strategic partnership that promises to propel the advancement of precision medicine and transform the solutions available to clinicians & patients.

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia”) is pleased to announce that its subsidiary, Advanced Development & Safety Laboratories (“ADSL”), has established a U.S.-based division (“ADSL USA”) to assist companies in navigating the evolving cosmetic regulatory landscape in the U.S.